Boston Scientific Corp. reports $20.07 billion revenue for fiscal year ended December 31, 2025, up 19.9%

ยท BSX

Boston Scientific Corp. reported revenue of $20.07 billion for the year ended December 31, 2025, an increase of 19.9% from the previous year ($16.75 billion).

For the same period it posted net income of $2.89 billion, up 56.7%, or $1.94 per diluted share (1.25 a year earlier).

That is a net margin of 14.4%.

On Sanad's AAOIFI Standard 21 screen, Boston Scientific Corp. is currently compliant: interest-bearing debt is 19.2% of market capitalisation (limit 30%), and impure income is 0.5% of revenue (limit 5%).

Source: 10-K filed with the U.S. Securities and Exchange Commission on February 17, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Boston Scientific Corp. news